Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease

Journal of Clinical Investigation

Volumn 101, Issue 6, 1998, Pages 1415-1423

  Pelet, Anna ^a   Geneste, Olivier ^b,c   Edery, Patrick ^a   Pasini, Andrea ^b   Chappuis, Sophie ^b   Attié, Tania ^a   Munnich, Arnold ^a   Lenoir, Gilbert ^b   Lyonnet, Stanislas ^a   Billaud, Marc ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Genetics; Hirschsprung's disease; Mutations; RET; Tyrosine kinase

Indexed keywords

GENE PRODUCT; TYROSINE KINASE RECEPTOR;

ANIMAL CELL; ARTICLE; ENZYME ACTIVITY; GENETICS; HIRSCHSPRUNG DISEASE; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT;

EID: 0032521177     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI375     Document Type: Article

References (51)

1. Hirschsprung, H. 1888. Stuhlträgheit neugeborener infolge von dilatation und hypertrophic des colons. Jb. Kinderheilk. 27:1.
2. Bolande, R. 1973. The neurocristopathies: a unifying concept of disease arising in neural crest maldevelopment. Hum. Pathol. 5:409-429.
3. Douarin, L. 1982. The Neural Crest. Cambridge University Press. Cambridge, United Kingdom.
4. Badner, J., W. Sieber, K. Garver, and A. Chakravarti. 1990. A genetic study of Hirschsprung disease. Am. J. Hum. Genet. 46:568-580.
5. Lyonnel, S., A. Bolino, A. Pelet, L. Abel, C. Nihoul-Fékété, M. Briard, V. Mok Siu, H. Kääriäinen, O. Martucciello, M. Lerone, et al. 1993. A gene for Hirschsprung disease maps to the proximal long arm of chromosome 10. Nat. Genet. 4:346-350.
6. Angrist, M., E. Kauffman, S.A. Slaugenhaupt, M. Cox Matise, E.G. Puffenberger, S.S. Washington, A. Lipson, D.T. Cass, T. Reyna, D.E. Weeks, et al. 1993. A gene for Hirschsprung disease (megacolon) in the pericentromeric region of human chromosome 10. Nat. Genet. 4:351-356.
7. Edery, P., S. Lyonnet, L. Mulligan, A. Pelet, E. Dow, L. Abel, S. Holder, C. Nihoul-Fekete, B. Ponder, and A. Munnich. 1994. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature. 367:378-380.
8. Romeo, G., P. Ronchetto, Y. Luo, V. Barone, M. Seri, I. Ceccherini, B. Pasini, R. Bacciardi, M. Lerone, H. Kääriäinen, et al. 1994. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature. 367:377-378.
9. Takahashi, M., Y. Buma, T. Iwamoto, Y. Inaguma, and H. Ikeda. 1988. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene. 3:571-578.
10. Durbec, P., C. Marcos-Gutierrez, C. Kilkenny, M. Grigoriou, K. Wartiowaara, P. Suvanto, P. Smith, B. Ponder, F. Costantini, M. Saarma, et al. 1996. Glial cell line-derived neurotrophic factor signaling through the Ret receptor tyrosine kinase. Nature. 381:789-793.
11. Jing, S., S. Jing, D. Wen, Y. Yu, P.L. Holst, Y. Luo, M. Fang, R. Tamir, L. Antonio, Z. Hu, et al. 1996. GDNF-induced activation of the Ret protein tyrosine kinase is mediated by GDNFR-α, a novel receptor for GDNF. Cell. 85: 1113-1124.
12. Treanor, J.J., L. Goodman, F. de Sauvage, D.M. Stone, K.T. Poulsen, C.D. Beck, C. Gray, M.P. Armanini, R.A. Pollock, F. Hefti, et al. 1996. Characterization of a multicomponent receptor for GDNF. Nature. 382:80-83.
13. Trupp, M., E. Arenas, M. Fainziiber, A. Nilsson, B. Sieber, M. Grigoriou, C. Kilkenny, E. Salazar-Grueso, V. Pachnis, U. Arumäes, et al. 1996. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature. 381:785-789.
14. Kotzbauer, P.T., P. Alampe, R.O. Heuckeroth, J.P. Golden, D.J. Credon, E.M. Johnson, Jr., and J. Milbrandt. 1996. Neurturin, a relative of glial-cell-line neurotrophic factor. Nature. 384:467-470.
15. Baloh, R.H., M.G. Tansey, J.P. Golden, D.J. Credon, R.O. Heuckeroth, C.L. Keck, D.B. Zimonjic, N.C. Popescu. E.M. Johnson, Jr., and J. Milbrandt. 1997. TrnR2, a novel receptor that mediates nurturin and GDNF signaling through RET. Neuron. 18:793-802.
16. Goodfellow, P. 1994. Inherited cancers associated with the RET protooncogene. Curr. Opin. Genet. Dev. 4:446-452.
17. Mulligan, E.M., and B.A. Ponder. 1995. Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J. Clin. Endocrinol. Metab. 80:1989-1995.
18. Pasini, B., I. Ceccherini, and G. Romeo. 1996. RET mutations in human disease. Trends Genet. 12:138-144.
19. Eng, C., D. Clayton, I. Schuffenecker, G. Lenoir, G. Cote, R.F. Gagel, H.K. Van Amstel, C.J. Lips, I. Nishisho, S.I. Takai, et al. 1996. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA (J. Am. Med. Assoc.). 276:1575-1579.
20. Santoro, M., F. Carlomagno, A. Romano, D.P. Bottaro, N.A. Dathan, M. Grieco, A. Fusco, G. Vecchio, B. Matoskova, M.H. Kraus, and P.P. Di Fiore. 1995. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science. 267:381-383.
21. Asai, N., T. Iwashita, M. Matsuyama, and M. Takahashi. 1995. Mechanism of activation of the ret proto-oncogene by endocrine neoplasia 2A mutations. Mol. Cell. Biol. 15:1613-1619.
22. Borrello, M.G., D.P. Smith, B. Pasini, I. Bongarzone, A. Greco, M.J. Lorenzo, E. Arighi, C. Miranda, C. Eng, L. Alberti, et al. 1995. RET activation by germline MEN2A and MEN2B mutations. Oncogene. 11:2419-2427.
23. Rossel, M., A. Pasini, S. Chappuis, O. Geneste, E. Fournier, I. Schuffenecker, M. Takahashi, L.A. Van Grunsven, J.L. Urdiales, B.B. Rudkin, et al. 1997. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations. Oncogene. 14:265-275.
24. Attié T., A. Pelet, P. Edery, C. Eng, L. Mulligan, J. Amiel, S. Beldjord, C. Nihoul-Fékété, A. Munnich, B. Ponder, and S. Lyonnet. 1995. Diversity of RET proto-oncogene mutations in Hirschsprunn's disease. Hum. Mol. Genet. 4: 2407-2409.
25. Pasini, B., M.G. Borello, A. Greco, I. Bongafzone, Y. Luo, P. Mondellini, L. Alberti, C. Miranda, E. Arighi, R. Bocciardi, et al. 1995. Loss of function effect of RET mutations causing Hirschsprung disease. Nat. Genet. 10:35-40.
26. Carlomagno, F., G. De Vita, M.T. Berlingieri, V. De Franciscis, R.M. Mellilo, V. Colantuoni, M.H. Kraus, P.P. Di Fiore, A. Fusco, and M. Santoro. 1996. Molecular heterogeneity of RET loss of function in Hirschsprung's disease. EMBO (Eur. Mol. Biol. Organ.) J. 15:2717-2725.
27. Iwashita, T., H. Murakami, N. Asai, and M. Takahashi, 1996. Mechanism of Ret dysfunction by Hirschsprung mutations affecting its extra cellular domain. Hum. Mol. Genet. 5:1578-1580.
28. Schuchardt, A., V. D'Agati, L. Larsson-Blomberg, F. Costantini, and V. Pachnis. 1994. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature. 367:380-383.
29. Mulligan, L.M., C. Eng, T. Attie, S. Lyonnet, D.J. Marsh, V.J. Hyland, B.G. Robinson, A. Frilling, C. Verellen-Dumoulin, A. Safar, et al. 1994. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum. Mol. Genet. 3:2163-2167.
30. Morgenstern, J.P., and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587-3596.
31. Pear, W.S., G.P. Nolan, M.L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA. 90:8392-8396.
32. D'Arcangelo, G., and S. Halegoua. 1993. A branched signaling pathway for nerve growth factor is revealed by Src-, Ras-, and Raf-mediated gene inductions. Mol. Cell. Biol. 13:3146-3155.
33. Taniguchi, M.I.T., M. Hamaguchi, M. Matsuyama, and M. Takahashi. 1991. The RET oncogene products are membrane-bound glycoproteins phosphorylated on tyrosine residues in vivo. Biochem. Biophys. Res. Commun. 181: 416-422.
34. Bonfini, L.M.E., G. Pelicci, L. Lanfrancone, and P.O. Pelicci. 1996. Not all She's roads lead to Ras. Trends Biochem. Sci. 21:257-261.
35. Asai, N., H. Murakami, T. Iwashita, and M. Takahashi, 1996. A mutation at tyrosine 1062 in MEN2A-RET and MEN2B-RET impairs their transforming activity and association with She adaptor proteins. J. Biol. Chem. 271: 17644-17649.
36. Arighi, E., L. Alberti, F. Torriti, S. Ghizzoni, M.G. Rizzetti, G. Pelici, B. Pasini, C. Bongarzone, C. Piutti, M.A. Pierotti, and M.G. Borrello. 1997. Identification of She docking site on Ret tyrosine kinase. Oncogene. 14:773-782.
37. Lorenzo, M.J., G.D. Gish, C. Houghton, T.J. Stonehouse, T. Pawson, B.A.J. Ponder, and D.P. Smith. 1997. RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of She, and the SH2 domain of Grb2. Oncogene. 14:763-771.
38. Shapiro, L.F.A., P.D. Kwong, A. Thompson, M.S. Lebmann, L.J. Grubel, J. Als-Nielsen, D.R. Colman, and W.A. Hendrickson. 1995. Structural basis of cell-cell adhesion by cadherins. Nature. 374:327-337.
39. Nagar, B.O.M., M. Ikura, and J.M. Rini. 1996. Structural basis of calcium-induced E-cadherin rigidification and dimerization. Nature. 380:360-364.
40. Takahashi, M., N. Asai, T. Iwashita, T. Isomura, K. Miyazaki, and M. Matsuyama. 1993. Characterization of the ret proto-oncogene products expressed in mouse L. cells. Oncogene. 8:2925-2929.
41. Iwashita, T., N. Asai, H. Murakami, M. Matsuyama, and M. Takahashi. 1996. Identification of tyrosine residues that are essential lor transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation. Oncogene. 12:481-487.
42. Pandey, A., H. Duan, P.P. Di Fiore, and V.M. Dixit. 1995. The Ret receptor protein tyrosine kinase associates with the SH2-containing adapter protein Grb10. J. Biol. Chem. 270:21461-21463.
43. Pandey, A., X. Liu, J.E. Dixon, P.P. Di Fiore, and V.M. Dixit. 1996. Direct association between the Ret receptor tyrosine kinase and the Src homology 2-containing adapter protein Grb7. J. Biol. Chem. 271:10607-10610.
44. Durick, K., R.Y. Wu, G.N. Gill, and S.S. Taylor. 1996. Mitogenic signaling by Ret/ptc2 requires association with enigma via a LIM domain. J. Biol. Chem. 271:12691-12694.
45. Hanks, S.K., A. Quinn, and T. Hunter. 1988. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science. 241:42-52.
46. Angrist, M., S. Bolk, B. Thiel, E. Puffenberger, R. Hofstra, C. Buys, and A. Chakravarti. 1995. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease. Hum. Mol. Genet. 4:821-830.
47. Carlomagno, F., G. Salvatore, A.M. Cirafici, G. De Vita, R.M. Melillo, V. De Franciscis, M. Billaud, A. Fusco, and M. Santoro. 1997. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res. 57:391-395.
48. Salomon, R., T. Attie, A. pelet, C. Bidaud, C. Eng, J. Amiel, S. Sarnacki, O. Goulet, C. Ricour, C. Nihoul-Fekete, et al. 1996. Germline mutations of the RET ligand, GDNF, are not sufficient to cause Hirschsprung disease. Nat. Genet. 14:345-347.
49. Angrist, M., S. Bolk, M. Halushka, P.A. Lapchak, and A. Chakravarti. 1996. Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient. Nat. Genet. 14:341-343.
50. Ivanchuk, S.M., S.M. Myers, C. Eng, and L.M. Mulligan. 1996. De novo mutation of GDNF, ligand for the RET/GDNFR-a receptor complex, in Hirschsprung disease. Hum. Mol. Genet. 5:2023-2026.
51. Ito, S., T. Iwashita, N. Asai, H. Murakami, Y. Iwata, G. Sobue, and M. Takahashi. 1997. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Cancer Res. 57:2870-2872.